Tamoxifen	Raloxifene	RR, 95% CI
CI = confidence interval; RR = relative risk; VTE = venous thromboembolism.
Invasive breast cancer	4.3	4.41	1.02, 0.82–1.28
Noninvasive breast cancer	1.51	2.11	1.4, 0.98–2.00
Uterine cancer	2.0	1.25	0.62, 0.35–1.08
VTE	3.8	2.6	0.7, 0.68–0.99
Cataracts	12.3	9.72	0.79, 0.68–0.92
Incidence of Symptoms (0–4 scale)
Favor Tamoxifen
Dyspareunia	0.68	0.78	P < .001
Musculoskeletal problems	1.10	1.15	P = .002
Weight gain	0.76	0.82	P < .001
Favor Raloxifene
Vasomotor symptoms	0.96	0.85	P < .001
Bladder control symptoms	0.88	0.73	P < .001
Leg cramps	1.10	0.91	P < .001
Gynecologic problems	0.29	0.19	P < .001